Tests magnesium against saline during cancer surgery with cisplatin
Tests magnesium against saline in adults with mesothelioma receiving cisplatin during surgery.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 130 people, planned
- Started
- 4 Apr 2023
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Magnesium sulfate
- Normal Saline
- Record updated
- 21 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with malignant mesothelioma who are having surgery with heated chemotherapy (HIOC) given with cisplatin. It tests whether extra magnesium protects the kidneys.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Malignant mesothelioma, with surgery planned that includes HIOC.
Main reasons for not taking part
- Kidney function eGFR below 45 ml/min/1.73m2, or end-stage kidney disease treated with dialysis or similar
- Blood magnesium above 3 mg/dl
- Pregnant or breastfeeding
- Neuromuscular disease, such as myasthenia gravis or multiple sclerosis
- Coronary artery disease in the past year, or a slow heart rate (below 55 beats per minute) or high grade heart block without a pacemaker
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- • Adult patients (≥18 years old) with malignant mesothelioma undergoing surgery with HIOC with Dr. Raphael Bueno or another BWH thoracic surgeon
Who cannot take part
- Coronary artery disease, defined as any of the following in the prior year: a positive stress test; coronary angiogram indicating 1 or more vessels with >70% stenosis; percutaneous coronary intervention with stents; or coronary artery bypass graft surgery
- Positive COVID test in the 10 days prior to surgery
- Concurrent participation in a study with an alternative experimental therapy that may interact with IV Mg
- Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myositis)
- Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months
- Hypersensitivity to Mg sulfate
- Any condition that, in the view of the PI, might place the patient at increased risk or compromise the integrity of the study
- eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Screening labs refer to those obtained at the preoperative visit with the surgeon or within 90 days prior, whereas preoperative labs are obtained on the day of admission (typically one to three days priors to surgery)
- Serum Mg >3 mg/dl on either screening labs or preoperative labs
- Pregnant/breastfeeding
- High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker
- Prisoner
- Conflict with other study
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Shruti GuptaTaking people
About the trial
What the trial wants to find out
In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo
Read full original descriptionShow less
.
The 2 groups in the trial
- Magnesium SulfateTreatment being tested
The IV Mg will start at 1 g/hour (25 ml/hour) within one hour following induction of anesthesia and stabilization of the patient. The infusion will continue for 24 hours and serum Mg levels will be monitored every 4 hours (+/-1 hour) for 28 hours following initiation of the Mg. Dose adjustments to the Mg infusion will be made as necessary to reach target serum Mg levels (3-5 mg/dl).
- Normal SalinePlacebo, for comparison
Patients randomized to placebo will receive an equal volume of normal saline (0.9% NS) placebo which will be administered as a continuous infusion at 25 ml/hour. The infusion will continue for 24 hours.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI
- Plain-language title
- Tests magnesium against saline during cancer surgery with cisplatinGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 November 2025